

Katalin Keltai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6364916/publications.pdf>

Version: 2024-02-01

25
papers

3,725
citations

643344

15
h-index

651938

25
g-index

25
all docs

25
docs citations

25
times ranked

6430
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	1.4	6
2	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , 2021, 42, 2995-3007.	1.0	18
3	Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery. <i>JAMA Cardiology</i> , 2021, 6, 1042.	3.0	35
4	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	1.0	15
5	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	2.9	11
6	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	1.6	118
7	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , 2018, 39, 750-757a.	1.0	72
8	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2306-2315.	1.2	296
9	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 205-218.	6.3	426
10	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 219-229.	6.3	651
11	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	0.8	133
12	Electrosynthesized molecularly imprinted polystyrene nanofilms for human serum albumin detection. <i>Analytica Chimica Acta</i> , 2017, 977, 1-9.	2.6	73
13	Spiegelmers as potential receptors for cTnI diagnostics. <i>Analytical Methods</i> , 2017, 9, 5091-5093.	1.3	2
14	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2009-2020.	13.9	526
15	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2021-2031.	13.9	641
16	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2032-2043.	13.9	299
17	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016, 32, 311-318.	0.8	24
18	Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. <i>Circulation</i> , 2014, 129, 1568-1576.	1.6	324

#	ARTICLE	IF	CITATIONS
19	Doxorubicin selectively suppresses mRNA expression and production of endothelin-1 in endothelial cells. <i>Vascular Pharmacology</i> , 2010, 53, 209-214.	1.0	15
20	Endothelins: a Possible Mechanism of Cytostatics-induced Cardiomyopathy. <i>Leukemia and Lymphoma</i> , 2004, 45, 351-355.	0.6	7
21	Endothelin-1 and Cardiac Function in Anthracycline-treated Patients: A 1-year Follow-up. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S372-S375.	0.8	6
22	Effect of Incessant Ventricular Tachyarrhythmias on Serum Endothelin and Big-endothelin Levels. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S402-S406.	0.8	5
23	Endothelin Gene Expression During Ischemia and Reperfusion. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S198-S201.	0.8	6
24	Changes of Endothelin-1 and Big Endothelin-1 Levels and Action Potential Duration during Myocardial Ischemia-reperfusion in Dogs with and without Ventricular Fibrillation. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S376-S379.	0.8	13
25	Effects of implantable cardioverter defibrillator implantation and shock application on serum endothelin-1 and big-endothelin levels. <i>Clinical Science</i> , 2002, 103, 233S-236S.	1.8	3